Published in Value Health on October 28, 2009
Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. Circulation (2011) 2.44
Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug. Clinicoecon Outcomes Res (2015) 0.94
REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. Int J Technol Assess Health Care (2015) 0.82
When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives. Healthcare (Basel) (2015) 0.81
Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. Biomed Res Int (2015) 0.77
Beyond AWP . . . way beyond. Value Health (2009) 0.76
Economic evaluation of vaccines in Canada: A systematic review. Hum Vaccin Immunother (2016) 0.76
Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. Drugs Real World Outcomes (2016) 0.75
Integrating tobacco treatment into cancer care: Study protocol for a randomized controlled comparative effectiveness trial. Contemp Clin Trials (2016) 0.75
Methods to construct a step-by-step beginner's guide to decision analytic cost-effectiveness modeling. Clinicoecon Outcomes Res (2016) 0.75
US-Based Drug Cost Parameter Estimation for Economic Evaluations. Med Decis Making (2014) 0.75
What's in a perspective? Value Health (2009) 0.75
Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). Oncologist (2017) 0.75
The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies. Eur J Health Econ (2016) 0.75
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health (2013) 4.22
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93
The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry (2005) 3.92
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet (2002) 3.26
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health (2007) 3.05
Patterns and correlates of linkage to appropriate HIV care after HIV diagnosis in the US Medicaid population. Sex Transm Dis (2013) 2.92
Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol (2012) 2.82
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health (2008) 2.31
Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.25
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics (2013) 2.21
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ (2013) 2.21
Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Spec Pharm (2014) 2.03
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry (2005) 2.03
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy (2014) 2.02
Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy (2009) 1.94
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health (2013) 1.89
Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol (2010) 1.84
Cost-of-illness studies : a review of current methods. Pharmacoeconomics (2006) 1.84
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. BMC Health Serv Res (2009) 1.82
Patients' attitudes about living donor transplantation and living donor nephrectomy. Am J Kidney Dis (2003) 1.80
Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. Diabetes Care (2009) 1.79
Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med Care (2010) 1.75
What do international pharmacoeconomic guidelines say about economic data transferability? Value Health (2010) 1.74
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care (2013) 1.66
The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Ann Surg (2011) 1.63
Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics (2010) 1.55
Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value Health (2011) 1.53
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Clin Ther (2013) 1.53
Burden associated with chronic sleep maintenance insomnia characterized by nighttime awakenings among women with menopausal symptoms. Menopause (2010) 1.52
Amniocentesis and informed consent. Br Med J (Clin Res Ed) (1988) 1.52
Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health (2005) 1.50
Health disparities in staging of SEER-medicare prostate cancer patients in the United States. Urology (2010) 1.50
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. J Med Econ (2013) 1.49
Dental visits to hospital emergency departments by adults receiving Medicaid: assessing their use. J Am Dent Assoc (2002) 1.49
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med (2013) 1.44
Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. Urology (2011) 1.44
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health (2003) 1.43
Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state. Surg Obes Relat Dis (2012) 1.42
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. Am J Manag Care (2011) 1.39
Using evidence in the development of local health policies. Some evidence from the United Kingdom. Int J Technol Assess Health Care (2002) 1.35
Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care (2005) 1.31
Variation in average costs among federally sponsored state-organized cancer detection programs: economies of scale? Med Decis Making (2002) 1.28
Can economic evaluations be made more transferable? Eur J Health Econ (2005) 1.27
Best practice in undertaking and reporting health technology assessments. Working group 4 report. Int J Technol Assess Health Care (2002) 1.25
Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med (2005) 1.24
Center effects in anemia management of dialysis patients. J Am Soc Nephrol (2007) 1.22
Exploring donors' and recipients' attitudes about living donor kidney transplantation. Prog Transplant (2003) 1.22
The cost of poor sleep: workplace productivity loss and associated costs. J Occup Environ Med (2010) 1.20
Global eradication of measles: an epidemiologic and economic evaluation. J Infect Dis (2011) 1.19
Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS One (2011) 1.19
Economic evaluation of health interventions. BMJ (2008) 1.19
Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther (2009) 1.18
Whether New Cooperative Mmedical Schemes reduce the economic burden of chronic disease in rural China. PLoS One (2013) 1.17
Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Health Serv Res (2007) 1.16
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care (2012) 1.15
EBM, HTA, and CER: clearing the confusion. Milbank Q (2010) 1.15
The economic burden of opioid-related poisoning in the United States. Pain Med (2013) 1.13
Improving medical device regulation: the United States and Europe in perspective. Milbank Q (2014) 1.13
Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Med Care Res Rev (2006) 1.13
Estimating the costs of induced abortion in Uganda: a model-based analysis. BMC Public Health (2011) 1.13
Barriers to self-management of diabetes: a qualitative study among low-income minority diabetics. Ethn Dis (2011) 1.12
Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis. J Clin Psychiatry (2003) 1.11
Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Clin Trials (2013) 1.11
Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc (2009) 1.11
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health (2009) 1.11
Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv (2008) 1.10
Disparity implications of Medicare eligibility criteria for medication therapy management services. Health Serv Res (2010) 1.09
The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health (2007) 1.08
Retaining, and enhancing, the QALY. Value Health (2009) 1.08
Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics (2002) 1.06
The Role of HIT in Care Coordination in the United States. Med Care (2015) 1.06
The development of direct-to-consumer prescription drug advertising regulation. Food Drug Law J (2002) 1.06
Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health (2008) 1.06
Impact of an educational intervention for secondary prevention of myocardial infarction on Medicaid drug use and cost. Am J Manag Care (2004) 1.06
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health (2005) 1.05
Health economic evaluation: important principles and methodology. Laryngoscope (2013) 1.05
Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States. J Allergy Clin Immunol (2011) 1.05
A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clin Ther (2002) 1.05
The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications (2012) 1.03
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Med Res Methodol (2012) 1.03
Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation. Med Care (2009) 1.02
The National Program of Cancer Registries: explaining state variations in average cost per case reported. Prev Chronic Dis (2005) 1.02
Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Health Aff (Millwood) (2006) 1.02
The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable. Value Health (2003) 1.01
The effectiveness and cost-effectiveness of respite for caregivers of frail older people. J Am Geriatr Soc (2007) 1.01
Stakeholder engagement in patient-centered outcomes research: high-touch or high-tech? Expert Rev Pharmacoecon Outcomes Res (2014) 1.01
Colorectal cancer screening attitudes and practices in the general population: a risk-adjusted survey. J Public Health Manag Pract (2005) 1.00
A research agenda for economic evaluation of substance abuse services. J Subst Abuse Treat (2005) 1.00
Medication access through patient assistance programs. Am J Health Syst Pharm (2006) 1.00
Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics (2006) 0.99